Verona Pharma (VRNA) Earnings Call Presentation

Ohtuvayre® Commercial Performance and Opportunity - Ohtuvayre® Q1 2025 net sales reached approximately $71 million[7, 9, 56], with approximately 25,000 prescriptions filled[7, 32], and approximately 5,300 unique writers since launch[7, 55] - Ohtuvayre® launch has seen outstanding uptake, with approximately $114 million in net sales in the first 8 months[30] - Ohtuvayre® Q1 2025 dispensed prescriptions showed approximately 60% were refills[32, 55] - The company has approximately $401 million in cash and cash equivalents as of Q1 2025[9, 56] - Approximately 86 million maintenance-treated COPD patients represent a significant market opportunity for Ohtuvayre®[33, 45, 49] Pipeline Expansion and Clinical Development - The company is developing Ensifentrine for non-cystic fibrosis bronchiectasis, targeting approximately 370,000 US patients[16] - Phase 3 data for Ensifentrine showed an approximately 36% to 43% reduction in exacerbation rate compared to placebo[15] - The company is progressing activities for potential marketing authorization submissions, with Phase 3 data expected in Q2[51] Patent Protection and Market Strategy - The company has patent protection through the mid-2030s, with potential patent term extension on select patents[52, 53] - The company is focusing promotional efforts on approximately 8,500 offices, targeting approximately 12,000 HCPs[42, 43] - The company is pursuing strategic collaborations to maximize Ensifentrine's commercial value in regions outside the United States[47]